Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Discovery MM Services Inc

Neither a doctor nor a teaching hospital

Research payments

$724,602

181 payments

Through program year 2023, Discovery MM Services Inc is reported as receiving $724,602 in research payments, across 181 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $8,914 5
2022 Research $66,251 25
2021 Research $106,314 36
2020 Research $160,420 47
2019 Research $382,703 68

Breakdown

Who paid Research payments · program years 2019–2023
  1. AbbVie, Inc. $196,606 91 payments
  2. Sanofi US Services Inc. $163,706 26 payments
  3. Novo Nordisk AS $112,807 22 payments
  4. Supernus Pharmaceuticals, Inc. $106,575 10 payments
  5. Allergan Inc. $50,218 13 payments
  6. GlaxoSmithKline, LLC. $44,931 3 payments
  7. Amgen Inc. $27,675 10 payments
  8. Paratek Pharmaceuticals, Inc. $20,105 4 payments
  9. Sanofi-Aventis U.S. LLC $1,978 2 payments
Studies the money was for Research payments · program years 2019–2023
  1. A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Di $96,649 4 payments
  2. Nn2211-4232 $95,018 15 payments
  3. M16-100 $77,658 33 payments
  4. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $68,486 6 payments
  5. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $56,106 30 payments
  6. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $50,430 23 payments
  7. A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $41,397 1 payment
  8. Clinical Trial LIN-MD-64 Ped FC Trial 6-17 Ph3 $35,624 8 payments
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $32,936 16 payments
  10. Evaluation of Spn-812 Er 200 and 400 MG Efficacy and Safety in Children With Adhd - A Double-Blind, Placebo-Controlled, Pivotal Trial $32,905 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record